Fluvoxamine

Fluvoxamine
Clinical data
Pronunciationfloo-VAHK-sə-meen

UK: /fluːˈvɒksəmiːn/

US: /fluːˈvɑːksəˌmiːn/
Trade namesLuvox, others
AHFS/Drugs.comMonograph
MedlinePlusa695004
License data
Pregnancy
category
  • AU: C
Routes of
administration		By mouth
Drug classSelective serotonin reuptake inhibitor (SSRI)
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability53% (90% confidence interval: 44–62%)
Protein binding77–80%
MetabolismLiver (primarily O-demethylation)
Major: CYP2D6 or CYP1A2
Minor: CYP3A4, CYP2C19, and/or CYP1A2
Elimination half-life12–13 hours (single dose), 22 hours (repeated dosing)
ExcretionKidney (98%; 94% as metabolites, 4% as unchanged drug)
Identifiers
  • 2-{[(E)-{5-Methoxy-1-[4-(trifluoromethyl)phenyl] pentylidene}amino]oxy}ethanamine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.125.476 Edit this at Wikidata
Chemical and physical data
FormulaC15H21F3N2O2
Molar mass318.340 g·mol−1
3D model (JSmol)
  • FC(F)(F)c1ccc(\C(=N\OCCN)CCCCOC)cc1
  • InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+ checkY
  • Key:CJOFXWAVKWHTFT-XSFVSMFZSA-N checkY
 X markNcheckY (what is this?)  (verify)

Fluvoxamine, sold under the brand name Luvox among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is primarily used to treat major depressive disorder and, perhaps more especially, obsessive–compulsive disorder (OCD), but is also used to treat anxiety disorders such as panic disorder, social anxiety disorder, and post-traumatic stress disorder.

Fluvoxamine's side-effect profile is similar to that of other SSRIs. Common adverse effects include constipation, gastrointestinal problems, headache, anxiety, irritation, sexual problems, dry mouth, sleep problems, and an increased risk of suicide at the start of treatment. These effects appear to be significantly weaker than with other SSRIs, with the exception of gastrointestinal side-effects. In some patients, sexual dysfunction may persist even after the drug is discontinued, a condition known as post-SSRI sexual dysfunction; regulatory agencies including the European Medicines Agency and Health Canada have recommended that fluvoxamine's product labeling warn of this risk.

Fluvoxamine appears to be more tolerable than other SSRIs, particularly with respect to cardiovascular complications.

It is on the World Health Organization's List of Essential Medicines.

Medical uses

In many countries (e.g., Australia, the United Kingdom, and Russia) it is commonly used for major depressive disorder. Fluvoxamine is also approved in the United States for obsessive–compulsive disorder (OCD), and social anxiety disorder. In Japan, it is also approved to treat OCD, social anxiety disorder, and major depressive disorder. Fluvoxamine is indicated for children and adolescents with OCD. The NICE guidelines in the United Kingdom have, as of 2005, authorized its use for OCD in adults and adolescents of any age and children over the age of 7.[medical citation needed]

There is evidence that fluvoxamine is effective for generalised social anxiety in adults, although, as with other SSRIs, some of the results may be compromised by having been funded by pharmaceutical companies. Of the SSRIs, however, fluvoxamine, paroxetine, and sertraline do appear consistent as viable treatments for generalised social anxiety.

Fluvoxamine is also effective for treating a range of anxiety disorders in children and adolescents, including generalized anxiety disorder, social anxiety disorder, panic disorder, and separation anxiety disorder.

The drug works long-term, and retains its therapeutic efficacy for at least one year.

The average therapeutic dose for fluvoxamine is 100 to 300 mg/day, with 300 mg being the upper daily limit normally recommended. OCD, however, often requires higher doses; doses of up to 450 mg/day may be prescribed in this case. The (off-label) upper daily limits for other serotonin-reuptake inhibitors used in the treatment of OCD, by analogy, are 400 mg for sertraline, 100 mg for paroxetine, 120 mg for both fluoxetine and citalopram, 60 mg for escitalopram and 300 mg for clomipramine.

In any case with fluvoxamine, treatment is generally begun at 50 mg and increased in 50 mg increments every 4 to 7 days until a therapeutic optimum is reached.

Adverse effects

Fluvoxamine's side-effect profile is very similar to other SSRIs. Gastrointestinal side effects are characteristic of those receiving treatment with fluvoxamine. However, compared to escitalopram and sertraline, fluvoxamine's gastrointestinal profile may be less intense, often being limited to nausea. Mosapride has demonstrated efficacy in treating fluvoxamine-induced nausea. It is also advised practice to divide total daily doses of fluvoxamine greater than 100 mg, with the higher fraction being taken in the evening (e.g., 50 mg at the beginning of the waking day and 200 mg at bedtime). In any case, high starting daily doses of fluvoxamine rather than the recommended gradual titration (starting at 50 mg and gradually titrating, up to 300 mg if necessary) may increase the likelihood of nausea.

In comparison to other SSRIs, fluvoxamine has the second highest rate of causing discontinuation syndrome, as a result of the low half-life of fluvoxamine.

Common

Common side effects occurring with 1–10% incidence:

Uncommon

Uncommon side effects occurring with 0.1–1% incidence:

  • Arthralgia
  • Confusional state
  • Cutaneous hypersensitivity reactions (e.g. oedema [buildup of fluid in the tissues], rash, pruritus)
  • Extrapyramidal side effects (e.g. dystonia, parkinsonism, tremor, etc.)
  • Hallucination
  • Orthostatic hypotension

Rare

Rare side effects occurring with 0.01–0.1% incidence:

  • Abnormal hepatic (liver) function
  • Galactorrhoea (expulsion of breast milk unrelated to pregnancy or breastfeeding)
  • Mania
  • Photosensitivity (being abnormally sensitive to light)
  • Seizures

Unknown frequency

Post-SSRI sexual dysfunction

Post-SSRI sexual dysfunction (PSSD) is an iatrogenic condition in which sexual side effects persist after discontinuation of serotonin reuptake inhibiting antidepressants, including fluvoxamine. Characteristic symptoms include genital numbness, pleasureless or weak orgasm, loss of libido, and erectile dysfunction; non-sexual symptoms such as emotional blunting and cognitive impairment may also occur. The condition can arise after even brief exposure to a serotonin reuptake inhibitor and may persist indefinitely; there is currently no established treatment. The DSM-5 noted in 2013 that serotonin reuptake inhibitor-induced sexual dysfunction may persist after the agent is discontinued.

A 2023 retrospective cohort study of over 12,000 males estimated the risk of irreversible sexual dysfunction at approximately 0.46% of patients treated with serotonergic antidepressants, including SSRIs, though the actual prevalence remains uncertain and the condition is likely underreported. A 2023 systematic review noted that while data on fluvoxamine is more limited than for some other SSRIs, it was included in the EMA's class-wide signal assessment and cases have been reported with SNRIs, SRI tricyclic antidepressants, and other serotonin reuptake inhibiting drugs in addition to SSRIs. A citizen petition submitted to regulators in 2018 suggested that SNRIs and other serotonin reuptake inhibiting drugs, including fluvoxamine, may be less likely to induce PSSD than SSRIs, though this remains unconfirmed.

In 2019, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) reviewed evidence on fluvoxamine as part of its class-wide signal assessment and recommended that product labels for all SSRIs and SNRIs be updated to state that sexual dysfunction may be long-lasting even after treatment is stopped. Health Canada followed with similar label updates in 2021. In 2024, Australia's Therapeutic Goods Administration aligned all SSRI and SNRI product information to reflect this risk; fluvoxamine was among the products requiring updated warnings.

Interactions

Luvox (fluvoxamine) 100 mg film-coated scored tablets

Fluvoxamine inhibits the following cytochrome P450 enzymes:[excessive citations]

By so doing, fluvoxamine can increase serum concentration of the substrates of these enzymes.

Fluvoxamine may also elevate plasma levels of olanzapine by approximately two times. Combined olanzapine and fluvoxamine, which may cause increased sedation, should be used cautiously and controlled clinically and by therapeutic drug monitoring to avoid olanzapine induced adverse effects and/or intoxication.

The plasma levels of oxidatively metabolized benzodiazepines (e.g., triazolam, midazolam, alprazolam, and diazepam) are likely to be increased when co-administered with fluvoxamine. However, the clearance of benzodiazepines metabolized by glucuronidation (e.g., lorazepam; oxazepam, which is coincidentally a metabolite of diazepam; temazepam) are not affected by fluvoxamine and may be safely taken alongside fluvoxamine should concurrent treatment with a benzodiazepine be necessary. Additionally, it appears that benzodiazepines metabolized by nitro-reduction (clonazepam, nitrazepam) may also, in a somewhat similar vein, be unlikely to be affected by fluvoxamine.

Using fluvoxamine and alprazolam together can increase alprazolam plasma concentrations. If alprazolam is coadministered with fluvoxamine, the initial alprazolam dose should be reduced to the lowest effective dose.

As with all SSRI medications, using fluvoxamine with NSAIDs like ibuprofen may increase the risk of bleeding, particularly in the GI tract.

Fluvoxamine is contraindicated with other medications that increase serotonin (dextromethorphan, ondansetron, amphetamine, sumatriptan, Tramadol, Hypericum perforatum, etc.). Combining these medications may rarely lead to a life-threatening complication known as serotonin syndrome.

Fluvoxamine and ramelteon coadministration is not indicated.

Fluvoxamine has been observed to increase serum concentrations of mirtazapine, which is mainly metabolized by CYP1A2, CYP2D6, and CYP3A4, by three- to four-fold in humans. Caution and adjustment of dosage as necessary are warranted when combining fluvoxamine and mirtazapine.

Fluvoxamine seriously affects the pharmacokinetics of tizanidine and increases the intensity and duration of its effects. Because of the potentially hazardous consequences, the concomitant use of tizanidine with fluvoxamine, or other potent inhibitors of CYP1A2, should be avoided.

When a beta-blocker is required, atenolol, pindolol and, possibly, metoprolol may be safer choices than propranolol, as the latter's metabolism is seriously, potentially dangerously, inhibited by fluvoxamine. Indeed, fluvoxamine may increase propranolol blood-levels by five-fold.

Clomipramine increases fluvoxamine levels and, conversely-likewise, fluvoxamine increases clomipramine levels (thereby its serotonergic potential) and inhibits its metabolism to its strongly-noradrenergic metabolite, norclomipramine.

Pharmacology

Pharmacodynamics

Receptor affinity profile
SiteKi (nM)
SERTTooltip Serotonin transporter2.5
NETTooltip Norepinephrine transporter1427
5-HT2C5786
α1-adrenergic1288
σ136

Fluvoxamine is a potent selective serotonin reuptake inhibitor with around 100-fold affinity for the serotonin transporter over the norepinephrine transporter. It has negligible affinity for the dopamine transporter or any other site, with the sole exception of the σ1 receptor. It behaves as a potent agonist at this receptor and has the highest affinity (36 nM) of any SSRI for doing so. This may contribute to its antidepressant and anxiolytic effects and may also afford it some efficacy in treating the cognitive symptoms of depression. It increases concentrations of the neurosteroid allopregnanolone, which may also contribute to its anxiolytic effects. Unlike some other SSRIs, fluvoxamine's metabolites are pharmacologically neutral.

Pharmacokinetics

Literature reviews have stated that fluvoxamine is metabolized primarily by CYP2D6 and to a minor extent by CYP1A2. However, CYP2D6 poor metabolizers do not have considerably higher fluvoxamine levels than extensive metabolizers. Fluvoxamine inhibits oxidative drug metabolising enzymes (particularly CYP1A2, and less potently CYP3A4 and CYP2D6) The mean plasma half-life of fluvoxamine after multiple oral doses of 100 mg/day in healthy, young volunteers was 13.6-15.6 hours. In the elderly, however the half life ranged from 17.4 to 25.9. Steady-state plasma fluvoxamine concentrations were 2-3 fold higher in children than in adolescents.

History

Fluvoxamine was developed by Kali-Duphar, part of Solvay Pharmaceuticals, Belgium, now Abbott Laboratories, and introduced as Floxyfral in Switzerland in 1983. It was approved by the U.S. Food and Drug Administration (FDA) in 1994, and introduced as Luvox in the US. In India, it is available, among several other brands, as Uvox by Abbott. It was one of the first SSRI antidepressants to be launched, and is prescribed in many countries to patients with major depression. It was the first SSRI, a non-TCA drug, approved by the U.S. FDA specifically for the treatment of OCD. At the end of 1995, more than ten million patients worldwide had been treated with fluvoxamine.[failed verification] Fluvoxamine was the first SSRI to be registered for the treatment of obsessive compulsive disorder in children by the FDA in 1997. In Japan, fluvoxamine was the first SSRI to be approved for the treatment of depression in 1999 and was later in 2005 the first drug to be approved for the treatment of social anxiety disorder. Fluvoxamine was the first SSRI approved for clinical use in the United Kingdom. Manufacturers include BayPharma, Synthon, and Teva, among others.

Research directions

A 2022 review concluded that according to low-certainty evidence, fluvoxamine may slightly decrease all-cause mortality by day 28 and potentially reduce the risk of hospitalization or death in outpatients with mild COVID-19. While early studies have suggested potential benefits for fluvoxamine as an anti-inflammatory agent and a possible impact on reducing cytokine storms, further studies did not confirm this expected benefit on COVID-19 patients. A cytokine storm refers to an excessive immune response characterized by a release of large amounts of pro-inflammatory cytokines.

In May 2022, based on a review of available scientific evidence, the U.S. Food and Drug Administration (FDA) did not issue an emergency use authorization covering the use of fluvoxamine to treat COVID-19, saying that, at the time, the data was not sufficient to conclude that fluvoxamine may be effective in treating non-hospitalized people with COVID-19 to prevent serious illness or hospitalization. The agency stated that the available study results were not conclusive on whether fluvoxamine is effective for this use.

Reviews published in 2024 indicate that clinical trials have shown fluvoxamine to be more effective than a placebo in reducing clinical deterioration and hospitalization in COVID-19 patients, particularly those taking 200 mg or more daily.

Environment

Fluvoxamine is a common finding in waters near human settlement. Christensen et al. 2007 finds it is "very toxic to aquatic organisms" by European Union standards.

References

  1. ↑ Use During Pregnancy and Breastfeeding, drugs.com
  2. ↑ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  3. 1 2 3 4 5 6 7 "Product Information Luvox". TGA eBusiness Services. Abbott Australasia Pty Ltd. 15 January 2013. Archived from the original on 9 October 2017. Retrieved 21 October 2013.
  4. ↑ van Harten J (March 1993). "Clinical pharmacokinetics of selective serotonin reuptake inhibitors". Clinical Pharmacokinetics. 24 (3): 203–220. doi:10.2165/00003088-199324030-00003. PMID 8384945. S2CID 84636672.
  5. 1 2 3 4 Altamura AC, Caldiroli A, Buoli M (April 2015). "Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders". Expert Opinion on Drug Metabolism & Toxicology. 11 (4): 649–660. doi:10.1517/17425255.2015.1021331. PMID 25728382.
  6. 1 2 3 Wyska E (October 2019). "Pharmacokinetic considerations for current state-of-the-art antidepressants". Expert Opinion on Drug Metabolism & Toxicology. 15 (10): 831–847. doi:10.1080/17425255.2019.1669560. PMID 31526279.
  7. ↑ "Luvox". ChemSpider. Royal Society of Chemistry. Archived from the original on 15 November 2013. Retrieved 21 October 2013.
  8. ↑ "Fluvoxamine Maleate Information". FDA.gov. US Food and Drug Administration. 15 July 2015. Archived from the original on 29 November 2019. Retrieved 28 November 2019.
  9. 1 2 McCain JA (July 2009). "Antidepressants and suicide in adolescents and adults: a public health experiment with unintended consequences?". P & T: A Peer-Reviewed Journal for Formulary Management. 34 (7): 355–378. PMC 2799109. PMID 20140100.
  10. ↑ Walkup JT, Labellarte MJ, Riddle MA, et al. (April 2001). "Fluvoxamine for the treatment of anxiety disorders in children and adolescents". The New England Journal of Medicine. 344 (17): 1279–1285. doi:10.1056/NEJM200104263441703. PMID 11323729.
  11. ↑ Figgitt DP, McClellan KJ (October 2000). "Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders". Drugs. 60 (4): 925–954. doi:10.2165/00003495-200060040-00006. PMID 11085201. S2CID 265712201.
  12. 1 2 Irons J (December 2005). "Fluvoxamine in the treatment of anxiety disorders". Neuropsychiatric Disease and Treatment. 1 (4): 289–299. PMC 2424117. PMID 18568110.
  13. ↑ Asnis GM, Hameedi FA, Goddard AW, et al. (August 2001). "Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients". Psychiatry Research. 103 (1): 1–14. doi:10.1016/S0165-1781(01)00265-7. PMID 11472786. S2CID 40412606.
  14. ↑ Vezmar S, Miljkovic B, Vucicevic K, et al. (May 2009). "Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression". Journal of Pharmacological Sciences. 110 (1): 98–104. doi:10.1254/jphs.09013fp. PMID 19444001.
  15. 1 2 3 Healy D, Bahrick A, Bak M, et al. (2022). "Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin". International Journal of Risk & Safety in Medicine. 33 (1): 65–76. doi:10.3233/JRS-210023. PMC 8925105. PMID 34719438.
  16. 1 2 "PRAC recommendations on signals adopted at the 13-16 May 2019 PRAC meeting" (PDF). European Medicines Agency. 11 June 2019. Retrieved 8 April 2026.
  17. 1 2 Westenberg HG, Sandner C (April 2006). "Tolerability and safety of fluvoxamine and other antidepressants". International Journal of Clinical Practice. 60 (4): 482–491. doi:10.1111/j.1368-5031.2006.00865.x. PMC 1448696. PMID 16620364.
  18. ↑ Organization WH (2023). The selection and use of essential medicines: web annex A: World Health Organization model list of essential medicines: 23rd list. Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  19. 1 2 Rossi S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
  20. ↑ "Luvox Tablets". NPS MedicineWise. Archived from the original on 22 October 2018. Retrieved 22 October 2018.
  21. 1 2 British National Formulary (BNF) (65th ed.). London, UK: Pharmaceutical Press. 2013. ISBN 978-0-85711-084-8.
  22. ↑ "Summary of Full Prescribing Information: Fluvoxamine". Drug Registry of Russia (RLS) Drug Compendium (in Russian). Archived from the original on 2 April 2015. Retrieved 21 March 2015.
  23. 1 2 "Fluvoxamine Maleate tablet, coated prescribing information". DailyMed. U.S. National Library of Medicine. 14 December 2018. Archived from the original on 19 October 2020. Retrieved 28 November 2019.
  24. ↑ "Luvox CR approved for OCD and SAD". MPR. 29 February 2008. Archived from the original on 28 August 2021. Retrieved 2 March 2019.
  25. ↑ "2005 News Releases". Astellas Pharma. Archived from the original on 16 September 2018. Retrieved 16 September 2018.
  26. ↑ "International Approvals: Ebixa, Depromel/Luvox, M-Vax". www.medscape.com. Archived from the original on 29 October 2020. Retrieved 16 September 2018.
  27. ↑ "Fluvoxamine Product Insert" (PDF). Jazz Pharmaceuticals, Inc. U.S. Food and Drug Administration. March 2005. Archived from the original (PDF) on 4 November 2022. Retrieved 4 November 2022.
  28. ↑ Williams T, Hattingh CJ, Kariuki CM, et al. (October 2017). "Pharmacotherapy for social anxiety disorder (SAnD)". The Cochrane Database of Systematic Reviews. 10 (10) CD001206. doi:10.1002/14651858.CD001206.pub3. PMC 6360927. PMID 29048739.
  29. ↑ Liu X, Li X, Zhang C, et al. (July 2018). "Efficacy and tolerability of fluvoxamine in adults with social anxiety disorder: A meta-analysis". Medicine. 97 (28) e11547. doi:10.1097/MD.0000000000011547. PMC 6076099. PMID 29995828.
  30. ↑ Williams, T., McCaul, M., Schwarzer, G., Cipriani, A., Stein, D. J., & Ipser, J. (2020). Pharmacological treatments for social anxiety disorder in adults: a systematic review and network meta-analysis. Acta neuropsychiatrica, 32(4), 169–176. https://doi.org/10.1017/neu.2020.6 Archived 7 September 2024 at the Wayback Machine
  31. ↑ Davidson J. R. (2003). Pharmacotherapy of social phobia. Acta psychiatrica Scandinavica. Supplementum, (417), 65–71. https://doi.org/10.1034/j.1600-0447.108.s417.7.x Archived 7 September 2024 at the Wayback Machine
  32. ↑ "Antidepressants for children and teenagers: what works for anxiety and depression?". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 3 November 2022. doi:10.3310/nihrevidence_53342. S2CID 253347210. Archived from the original on 5 November 2022. Retrieved 7 November 2022.
  33. ↑ Boaden K, Tomlinson A, Cortese S, et al. (2 September 2020). "Antidepressants in Children and Adolescents: Meta-Review of Efficacy, Tolerability and Suicidality in Acute Treatment". Frontiers in Psychiatry. 11 717. doi:10.3389/fpsyt.2020.00717. PMC 7493620. PMID 32982805.
  34. ↑ Correll CU, Cortese S, Croatto G, et al. (June 2021). "Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review". World Psychiatry. 20 (2): 244–275. doi:10.1002/wps.20881. PMC 8129843. PMID 34002501.
  35. ↑ Wilde MI, Plosker GL, Benfield P (November 1993). "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness". Drugs. 46 (5): 895–924. doi:10.2165/00003495-199346050-00008. PMID 7507038. S2CID 195691900.
  36. ↑ Seibell PJ, Hamblin RJ, Hollander E. Obsessive-compulsive disorder: Overview and standard treatment strategies. Psychiatric Annals. 2015 Jun 1;45(6):297-302.
  37. ↑ Rivas-Vazquez, R.A., and Blais, M.A., 1997. Selective serotonin reuptake inhibitors and atypical antidepressants: A review and update for psychologists. Professional Psychology: Research and Practice, 28(6), p.526.
  38. ↑ Middleton, R., Wheaton, M.G., Kayser, R., and Simpson, H.B., 2019. Treatment resistance in obsessive-compulsive disorder. Treatment resistance in psychiatry: risk factors, biology, and management, pp.165-177.
  39. ↑ Ninan PT, Koran LM, Kiev A, Davidson JR, Rasmussen SA, Zajecka JM, Robinson DG, Crits-Christoph P, Mandel FS, Austin C. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry. 2006 Jan;67(1):15-22. doi: 10.4088/jcp.v67n0103. PMID 16426083.
  40. ↑ "Psychopharmacology Institute". psychopharmacologyinstitute.com.
  41. ↑ Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB; American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007 Jul;164(7 Suppl):5-53. PMID 17849776.
  42. ↑ Figgitt, D.P., and McClellan, K.J., 2000. Fluvoxamine: an updated review of its use in the management of adults with anxiety disorders. Drugs, 60, pp.925-954.
  43. ↑ Taylor D, Paton C, Shitij K (2012). The Maudsley prescribing guidelines in psychiatry. West Sussex: Wiley-Blackwell. ISBN 978-0-470-97948-8.
  44. ↑ "Faverin 100 mg film-coated tablets – Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Abbott Healthcare Products Limited. 14 May 2013. Archived from the original on 21 October 2013. Retrieved 21 October 2013.
  45. ↑ Oliva V, Lippi M, Paci R, et al. (July 2021). "Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis". Progress in Neuro-psychopharmacology & Biological Psychiatry. 109 110266. Elsevier BV. doi:10.1016/j.pnpbp.2021.110266. hdl:11390/1329975. PMID 33549697. S2CID 231809760.
  46. ↑ Ueda N, Yoshimura R, Shinkai K, et al. (November 2001). "Characteristics of fluvoxamine-induced nausea". Psychiatry Research. 104 (3). Elsevier BV: 259–264. doi:10.1016/s0165-1781(01)00320-1. PMID 11728615. S2CID 38761139.
  47. ↑ Ware MR (1 March 1997). "Fluvoxamine: A Review of the Controlled Trials in Depression". The Journal of Clinical Psychiatry. 58 (suppl 5). Physicians Postgraduate Press, Inc.: 15–23. ISSN 0160-6689. PMID 9184623. Archived from the original on 6 December 2022. Retrieved 1 December 2023.
  48. ↑ Hosenbocus S, Chahal R (February 2011). "SSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents". Journal of the Canadian Academy of Child and Adolescent Psychiatry. 20 (1): 60–67. ISSN 2293-6122. PMC 3024727. PMID 21286371.
  49. ↑ Szalavitz M (7 January 2011). "Top Ten Legal Drugs Linked to Violence". Time. Archived from the original on 21 September 2014. Retrieved 10 September 2014.
  50. ↑ Bala A, Tue Nguyen HM, Hellstrom WJ (January 2018). "Post-SSRI Sexual Dysfunction: A Literature Review". Sexual Medicine Reviews. 6 (1): 29–34. doi:10.1016/j.sxmr.2017.07.002. PMID 28778697.
  51. ↑ Healy D, Le Noury J, Mangin D (2018). "Enduring sexual dysfunction after treatment with antidepressants, 5-alpha-reductase inhibitors and isotretinoin: 300 cases". International Journal of Risk & Safety in Medicine. 29 (3–4): 125–134. doi:10.3233/JRS-180744. PMC 6004900. PMID 29733030.
  52. 1 2 3 Healy D, Mangin D (2024). "Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence". Epidemiology and Psychiatric Sciences. 33 (5) e52. doi:10.1017/S2045796024000532. PMC 11450419. PMID 39363727.
  53. ↑ Ben-Sheetrit J, Aizenberg D, Csoka AB, et al. (April 2023). "Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants". Annals of General Psychiatry. 22 (1) 15. doi:10.1186/s12991-023-00447-0. PMC 10122283. PMID 37076856.
  54. ↑ Tarchi L, Merola GP, Ferrara M, et al. (October 2023). "Selective serotonin reuptake inhibitors, post-treatment sexual dysfunction and persistent genital arousal disorder: A systematic review". Pharmacoepidemiology and Drug Safety. 32 (10): 1041–1055. doi:10.1002/pds.5653. hdl:2158/1317239. PMC 10332226. PMID 37345683.
  55. ↑ "Updated warnings about persistent sexual dysfunction for antidepressants". Therapeutic Goods Administration. 23 May 2024. Retrieved 8 April 2026.
  56. 1 2 Ciraulo DA, Shader RI (2011). Ciraulo DA, Shader RI (eds.). Pharmacotherapy of Depression (2nd ed.). Springer. p. 49. doi:10.1007/978-1-60327-435-7. ISBN 978-1-60327-435-7.
  57. 1 2 Brunton L, Chabner B, Knollman B (2010). Goodman and Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07-162442-8.
  58. ↑ Baumann P (December 1996). "Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors". Clinical Pharmacokinetics. 31 (6): 444–469. doi:10.2165/00003088-199631060-00004. PMID 8968657. S2CID 31923953.
  59. ↑ DeVane CL, Gill HS (1997). "Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design". The Journal of Clinical Psychiatry. 58 (Suppl 5): 7–14. PMID 9184622.
  60. ↑ DeVane CL (1998). "Translational pharmacokinetics: current issues with newer antidepressants". Depression and Anxiety. 8 (Suppl 1): 64–70. doi:10.1002/(SICI)1520-6394(1998)8:1+<64::AID-DA10>3.0.CO;2-S. PMID 9809216. S2CID 22297498.
  61. ↑ Bondy B, Spellmann I (March 2007). "Pharmacogenetics of antipsychotics: useful for the clinician?". Current Opinion in Psychiatry. 20 (2): 126–130. doi:10.1097/YCO.0b013e328017f69f. PMID 17278909. S2CID 23859992.
  62. ↑ Kroon LA (September 2007). "Drug interactions with smoking". American Journal of Health-System Pharmacy. 64 (18): 1917–1921. doi:10.2146/ajhp060414. PMID 17823102.
  63. ↑ Waknine Y (13 April 2007). "Prescribers Warned of Tizanidine Drug Interactions". Medscape News. Medscape. Archived from the original on 21 February 2013. Retrieved 1 February 2008.
  64. ↑ "Fluvoxamine (Oral Route) Precautions". Mayo Clinic. Archived from the original on 6 March 2019. Retrieved 2 November 2018.
  65. 1 2 Hemeryck A, Belpaire FM (February 2002). "Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update". Current Drug Metabolism. 3 (1): 13–37. doi:10.2174/1389200023338017. PMID 11876575.
  66. ↑ "Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers". FDA. 26 May 2021. Archived from the original on 4 November 2020. Retrieved 25 December 2020.
  67. ↑ Spina E, de Leon J (January 2007). "Metabolic drug interactions with newer antipsychotics: a comparative review". Basic & Clinical Pharmacology & Toxicology. 100 (1): 4–22. doi:10.1111/j.1742-7843.2007.00017.x. PMID 17214606.
  68. ↑ Bogetto F, Bellino S, Vaschetto P, et al. (October 2000). "Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial". Psychiatry Research. 96 (2): 91–98. doi:10.1016/s0165-1781(00)00203-1. PMID 11063782. S2CID 43395897.
  69. ↑ Hiemke C, Peled A, Jabarin M, et al. (October 2002). "Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects". Journal of Clinical Psychopharmacology. 22 (5): 502–506. doi:10.1097/00004714-200210000-00010. PMID 12352274. S2CID 38073367.
  70. ↑ "Movox". NPS MedicineWise. 23 November 2020. Archived from the original on 4 November 2022. Retrieved 4 November 2022.
  71. ↑ Dinis-Oliveira RJ (November 2017). "Metabolic profile of oxazepam and related benzodiazepines: clinical and forensic aspects". Drug Metabolism Reviews. 49 (4): 451–463. doi:10.1080/03602532.2017.1377223. PMID 28903606. S2CID 4528255.
  72. ↑ Raouf M (2016). Fudin J (ed.). "Benzodiazepine Metabolism and Pharmacokinetics" (PDF). Archived (PDF) from the original on 12 July 2018. Retrieved 16 September 2018.
  73. ↑ Peppers MP (1996). "Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease". Pharmacotherapy. 16 (1): 49–57. doi:10.1002/j.1875-9114.1996.tb02915.x. PMID 8700792. S2CID 1389910.
  74. ↑ "fluvoxamine maleate: PRODUCT MONOGRAPH" (PDF). 2016. Archived (PDF) from the original on 16 September 2018. Retrieved 16 September 2018.
  75. ↑ "Luvox Data Sheet" (PDF). Medsafe, New Zealand. 2017. Archived from the original (PDF) on 29 March 2018. Retrieved 16 September 2018.
  76. ↑ "Faverin Tablets". NPS MedicineWise. July 2022. Archived from the original on 4 November 2022. Retrieved 4 November 2022.
  77. ↑ Suzuki Y, Shioiri T, Muratake T, et al. (April 2003). "Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients: interaction with CYP2C19 mutated alleles". European Journal of Clinical Pharmacology. 58 (12): 829–833. doi:10.1007/s00228-003-0563-9. PMID 12698310. S2CID 32559753.
  78. ↑ Gerlach M, Warnke A, Greenhill L (2014). Psychiatric Drugs in Children and Adolescents: Basic Pharmacology and Practical Applications. Springer-Verlag Wien. p. 131. ISBN 978-3-7091-1500-8. Archived from the original on 10 January 2023. Retrieved 21 May 2020.
  79. ↑ Fleishaker JC, Hulst LK (1994). "A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine". European Journal of Clinical Pharmacology. 46 (1): 35–39. doi:10.1007/bf00195913. PMID 8005185. S2CID 2161450.
  80. ↑ Alam SM, Qasswal M, Ahsan MJ, et al. (August 2022). "Selective serotonin reuptake inhibitors increase risk of upper gastrointestinal bleeding when used with NSAIDs: a systemic review and meta-analysis". Scientific Reports. 12 (1) 14452. Bibcode:2022NatSR..1214452A. doi:10.1038/s41598-022-18654-2. PMC 9402708. PMID 36002638.
  81. ↑ Scotton WJ, Hill LJ, Williams AC, et al. (2019). "Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions". International Journal of Tryptophan Research. 12 1178646919873925. doi:10.1177/1178646919873925. PMC 6734608. PMID 31523132.
  82. ↑ Obach RS, Ryder TF (August 2010). "Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics". Drug Metabolism and Disposition: The Biological Fate of Chemicals. 38 (8): 1381–1391. doi:10.1124/dmd.110.034009. PMID 20478852. S2CID 8421997.
  83. ↑ Pandi-Perumal SR, Spence DW, Verster JC, et al. (12 April 2011). "Pharmacotherapy of insomnia with ramelteon: safety, efficacy and clinical applications". Journal of Central Nervous System Disease. 3: 51–65. doi:10.4137/JCNSD.S1611. PMC 3663615. PMID 23861638.
  84. 1 2 Anttila AK, Rasanen L, Leinonen EV (October 2001). "Fluvoxamine augmentation increases serum mirtazapine concentrations three- to fourfold". The Annals of Pharmacotherapy. 35 (10): 1221–1223. doi:10.1345/aph.1A014. PMID 11675851. S2CID 44807359.
  85. ↑ Granfors MT, Backman JT, Neuvonen M, et al. (April 2004). "Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction". Clinical Pharmacology and Therapeutics. 75 (4): 331–341. doi:10.1016/j.clpt.2003.12.005. PMID 15060511. S2CID 25781307.
  86. ↑ Perucca E, Gatti G, Spina E (September 1994). "Clinical pharmacokinetics of fluvoxamine". Clinical Pharmacokinetics. 27 (3): 175–190. doi:10.2165/00003088-199427030-00002. PMID 7988100. S2CID 22472247.
  87. ↑ Zanardi R, Serretti A, Rossini D, et al. (September 2001). "Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression". Biological Psychiatry. 50 (5): 323–330. doi:10.1016/s0006-3223(01)01118-0. PMID 11543734. S2CID 22692759.
  88. ↑ Sluzewska A, Szczawinska K (May 1996). "The effects of pindolol addition to fluvoxamine and buspirone in chronic mild stress model of depression". Behavioural Pharmacology. 7: 105.
  89. ↑ Mundo E, Guglielmo E, Bellodi L (September 1998). "Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study". International Clinical Psychopharmacology. 13 (5): 219–224. doi:10.1097/00004850-199809000-00005. PMID 9817627. S2CID 23946424.
  90. ↑ Belpaire FM, Wijnant P, Temmerman A, et al. (May 1998). "The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors". European Journal of Clinical Pharmacology. 54 (3): 261–264. doi:10.1007/s002280050456. PMID 9681670. S2CID 28105445.
  91. ↑ Xu ZH, Xie HG, Zhou HH (October 1996). "In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine". British Journal of Clinical Pharmacology. 42 (4): 518–521. doi:10.1046/j.1365-2125.1996.45319.x (inactive 2 August 2026). PMC 2042705. PMID 8904628.{{cite journal}}: CS1 maint: DOI inactive as of August 2026 (link)
  92. ↑ Belpaire FM, Wijnant P, Tammerman A, et al. (1997). "Inhibition of the oxidative metabolism of metoprolol by selective serotonin reuptake inhibitors in human liver microsomes". Fundamental and Clinical Pharmacology. 2 (11): 147.
  93. ↑ van Harten J (1995). "Overview of the pharmacokinetics of fluvoxamine". Clinical Pharmacokinetics. 29 (Suppl 1): 1–9. doi:10.2165/00003088-199500291-00003. PMID 8846617. S2CID 71812133.
  94. ↑ Muscatello MR, Spina E, Bandelow B, et al. (May 2012). "Clinically relevant drug interactions in anxiety disorders". Human Psychopharmacology. 27 (3): 239–253. doi:10.1002/hup.2217. PMID 22311403. S2CID 11592004.
  95. ↑ Szegedi A, Wetzel H, Leal M, et al. (June 1996). "Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data". The Journal of Clinical Psychiatry. 57 (6): 257–264. PMID 8666564.
  96. ↑ Hardy NE, Walkup JT (November 2021). "Clomipramine in Combination with Fluvoxamine: A Potent Medication Combination for Severe or Refractory Pediatric OCD". Journal of the Canadian Academy of Child and Adolescent Psychiatry. 30 (4): 273–277. PMC 8561855. PMID 34777510.
  97. ↑ Ishikawa M, Ishiwata K, Ishii K, et al. (October 2007). "High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503". Biological Psychiatry. 62 (8): 878–883. doi:10.1016/j.biopsych.2007.04.001. PMID 17662961. S2CID 728565.
  98. ↑ Schatzberg AF, Nemeroff CB (2009). The American Psychiatric Publishing textbook of psychopharmacology (4th ed.). Arlington, VA: American Psychiatric Pub. p. 354. ISBN 978-1-58562-386-0. OCLC 320111564.
  99. ↑ Yahata M, Chiba K, Watanabe T, et al. (September 2017). "Possibility of Predicting Serotonin Transporter Occupancy From the In Vitro Inhibition Constant for Serotonin Transporter, the Clinically Relevant Plasma Concentration of Unbound Drugs, and Their Profiles for Substrates of Transporters". Journal of Pharmaceutical Sciences. 106 (9): 2345–2356. Bibcode:2017JPhmS.106.2345Y. doi:10.1016/j.xphs.2017.05.007. PMID 28501470.
  100. 1 2 Hashimoto K (September 2009). "Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship". Central Nervous System Agents in Medicinal Chemistry. 9 (3): 197–204. doi:10.2174/1871524910909030197. PMID 20021354.
  101. ↑ Hindmarch I, Hashimoto K (April 2010). "Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered". Human Psychopharmacology. 25 (3): 193–200. doi:10.1002/hup.1106. PMID 20373470. S2CID 26491662.
  102. ↑ Uzunova V, Sheline Y, Davis JM, et al. (March 1998). "Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine". Proceedings of the National Academy of Sciences of the United States of America. 95 (6): 3239–3244. Bibcode:1998PNAS...95.3239U. doi:10.1073/pnas.95.6.3239. PMC 19726. PMID 9501247.
  103. ↑ Hrdina PD (July 1991). "Pharmacology of serotonin uptake inhibitors: focus on fluvoxamine". Journal of Psychiatry & Neuroscience. 16 (2 Suppl 1): 10–18. PMC 1188307. PMID 1931931.
  104. ↑ van Harten J (1995). "Overview of the pharmacokinetics of fluvoxamine". Clinical Pharmacokinetics. 29 Suppl 1: 1–9. doi:10.2165/00003088-199500291-00003. ISSN 0312-5963. PMID 8846617.
  105. ↑ "FDA prescribing information" (PDF). Archived from the original (PDF) on 19 October 2013.
  106. 1 2 Sittig's Pharmaceutical Manufacturing Encyclopedia (PDF) (3rd ed.). William Andrew. 2008. p. 1699. ISBN 978-0-8155-1526-5. Archived from the original (PDF) on 14 October 2013. Retrieved 17 October 2013.
  107. ↑ Leslie LK, Newman TB, Chesney PJ, et al. (July 2005). "The Food and Drug Administration's deliberations on antidepressant use in pediatric patients". Pediatrics. 116 (1): 195–204. doi:10.1542/peds.2005-0074. PMC 1550709. PMID 15995053.
  108. ↑ "Brand Index―Fluvoxamine India". Archived from the original on 19 October 2013. Retrieved 18 October 2013.
  109. ↑ Omori IM, Watanabe N, Nakagawa A, et al. (March 2010). "Fluvoxamine versus other anti-depressive agents for depression". The Cochrane Database of Systematic Reviews. 2013 (3) CD006114. doi:10.1002/14651858.CD006114.pub2. PMC 4171125. PMID 20238342.
  110. ↑ "OCD Medication". 24 February 2010. Archived from the original on 14 October 2013. Retrieved 17 October 2013.
  111. ↑ "Fluvoxamine Product Monograph" (PDF). 1999. Archived from the original (PDF) on 27 October 2020. Retrieved 15 September 2018.
  112. ↑ "Luvox Approved For Obsessive Compulsive Disorder in Children and Teens". Archived from the original on 16 January 2009. Retrieved 8 February 2014.
  113. ↑ Higuchi T, Briley M (February 2007). "Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan". Neuropsychiatric Disease and Treatment. 3 (1): 41–58. doi:10.2147/nedt.2007.3.1.41. PMC 2654524. PMID 19300537.
  114. ↑ Wishart DS, Guo AC, Oler E, et al. "Showing metabocard for Fluvoxamine (HMDB0014322)". Human Metabolome Database, HMDB. 5.0.
  115. ↑ "Solvay's Fluvoxamine maleate is first drug approved for the treatment of social anxiety disorder in Japan". Archived from the original on 15 September 2018. Retrieved 15 September 2018.
  116. ↑ Walker R, Whittlesea C, eds. (2007) [1994]. Clinical Pharmacy and Therapeutics (4th ed.). Edinburgh: Churchill Livingstone Elsevier. ISBN 978-0-7020-4293-5.
  117. ↑ "Fluvoxamine". www.drugbank.ca. Archived from the original on 4 November 2019. Retrieved 22 October 2019.
  118. ↑ Nyirenda JL, Sofroniou M, Toews I, et al. (September 2022). "Fluvoxamine for the treatment of COVID-19". The Cochrane Database of Systematic Reviews (Systematic review). 2022 (9) CD015391. doi:10.1002/14651858.CD015391. PMC 9473347. PMID 36103313.
  119. ↑ Bhuta S, Khokher W, Kesireddy N, et al. (2022). "Fluvoxamine in Nonhospitalized Patients With Acute COVID-19 Infection and the Lack of Efficacy in Reducing Rates of Hospitalization, Mechanical Ventilation, and Mortality in Placebo-Controlled Trials: A Systematic Review and Meta-Analysis". American Journal of Therapeutics. 29 (3): e298–e304. doi:10.1097/MJT.0000000000001496. PMID 35383578. S2CID 247978477.
  120. ↑ Asadi Anar M, Foroughi E, Sohrabi E, et al. (2022). "Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19". Frontiers in Pharmacology. 13 1036093. doi:10.3389/fphar.2022.1036093. PMC 9748354. PMID 36532776.
  121. ↑ Hu B, Huang S, Yin L (January 2021). "The cytokine storm and COVID-19". Journal of Medical Virology. 93 (1): 250–256. doi:10.1002/jmv.26232. PMC 7361342. PMID 32592501.
  122. ↑ "FDA declines to authorize common antidepressant as COVID treatment". Reuters. 16 May 2022. Archived from the original on 17 May 2022. Retrieved 18 May 2022.
  123. ↑ Memorandum Explaining Basis for Declining Request for Emergency Use Authorization of Fluvoxamine Maleate (PDF) (Memorandum). Food and Drug Administration. 16 May 2022. 4975580. Archived (PDF) from the original on 17 May 2022. Public Domain This article incorporates text from this source, which is in the public domain.
  124. ↑ Deng J, Moskalyk M, Zuo QK, et al. (January 2024). "Evaluating fluvoxamine for the outpatient treatment of COVID-19: A systematic review and meta-analysis". Reviews in Medical Virology. 34 (1) e2501. doi:10.1002/rmv.2501. PMID 38148036.
  125. ↑ Prasanth MI, Wannigama DL, Reiersen AM, et al. (June 2024). "A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications". Scientific Reports. 14 (1) 13462. Bibcode:2024NatSR..1413462P. doi:10.1038/s41598-024-64260-9. PMC 11166997. PMID 38862591.
  126. ↑ Zhou Q, Zhao G, Pan Y, et al. (2024). "The efficacy and safety of fluvoxamine in patients with COVID-19: A systematic review and meta-analysis from randomized controlled trials". PLOS ONE. 19 (5) e0300512. Bibcode:2024PLoSO..1900512Z. doi:10.1371/journal.pone.0300512. PMC 11098472. PMID 38753761.
  127. 1 2